11:02 PM
 | 
Aug 09, 2018
 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also participated, along with existing investors Arix Bioscience plc (LSE:ARIX), SV Health Investors, M Ventures, IP Group plc (LSE:IPO) and AbbVie Ventures. Details on the tranches are not disclosed.

Artios said the financing will allow it to advance its small molecule DNA damage response programs, including its lead program against DNA-directed DNA polymerase θ (POLθ), for cancer through clinical proof of concept (POC). CEO Niall Martin told BioCentury Artios expects to begin Phase Ia testing of the POLθ program by mid-2020.

Artios raised $36 million in a series A round in September 2016.

Andera's Raphael Wisniewski, LSP's Rene Kuijten and Pfizer Ventures's Barbara Dalton joined Artios' board.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD